- Catnip Might Be Your Next Mosquito Repellent
- COVID Death Rates 10 Times Higher in Countries Where Most Are Overweight: Report
- Health Highlights: March 4, 2021
- She Barely Survived a Severe Form of COVID-19 Hitting Kids
- Add Sleep Woes to Long-Term Effects of Concussions
- Opioid Addiction Relapse May Be Different for Men, Women
- Is Your Teen Unmotivated at School? That Might Change
- Could Taking a Swing at Golf Help Parkinson’s Patients?
- New Coronavirus Variant Out of Brazil Now in 5 U.S. States
- Vaping Pot Worse Than Vaping Tobacco for Teens’ Lungs: Study
Akynzeo Approved for Side Effects of Chemotherapy
The combination drug Akynzeo (netupitant and palonosetron) has been approved by the U.S. Food and Drug Administration to treat nausea and vomiting among people undergoing chemotherapy, the agency said Friday in a news release.
Akynzeo contains a new anti-nausea drug, netupitant, and palonosetron, which was approved to treat nausea and vomiting in 2008.
The combination drug’s effectiveness was evaluated in two clinical studies involving 1,720 people. The trials established that Akynzeo was more effective in preventing nausea and vomiting than palonosetron taken alone, the FDA said.
The most frequent side effects of the combination drug included headache, weakness, fatigue, indigestion and constipation.
Akynzeo is marketed and distributed by Eisai Inc. of Woodcliff Lake, N.J., under license from Switzerland-based Helsinn Healthcare.
More information
The FDA has more.
Source: HealthDay
